First blood to Roche in Hemlibra patent fight with Shire
Roche’s defence of its haemophilia drug Hemlibra against a patent infringement challenge by Shire has been buoyed by a Japanese ruling.
A Tokyo court has found in favour of the Swiss group and recommended that Shire’s challenge against majority-owned Japanese affiliate Chugai should be dismissed. While the ruling doesn’t have a direct bearing on additional challenges outside Japan, Roche has been buoyed by the result.
In a statement, the company said the court ruled that Hemlibra (emicizumab) “does not infringe patent 4313531, held by Shire’s wholly-owned subsidiaries Baxalta Inc and Baxalta GmbH”.
Read more: http://www.pmlive.com/pharma_news/first_blood_to_roche_in_hemlibra_patent_fight_with_shire_1229612
A Tokyo court has found in favour of the Swiss group and recommended that Shire’s challenge against majority-owned Japanese affiliate Chugai should be dismissed. While the ruling doesn’t have a direct bearing on additional challenges outside Japan, Roche has been buoyed by the result.
In a statement, the company said the court ruled that Hemlibra (emicizumab) “does not infringe patent 4313531, held by Shire’s wholly-owned subsidiaries Baxalta Inc and Baxalta GmbH”.
Read more: http://www.pmlive.com/pharma_news/first_blood_to_roche_in_hemlibra_patent_fight_with_shire_1229612